Equities researchers at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN – Get Free Report) in a note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
FibroGen Price Performance
NASDAQ:FGEN opened at $0.34 on Friday. The company has a market capitalization of $34.13 million, a price-to-earnings ratio of -0.14 and a beta of 0.70. The business has a 50 day moving average of $0.39 and a 200 day moving average of $0.89. FibroGen has a 1-year low of $0.30 and a 1-year high of $2.93.
FibroGen (NASDAQ:FGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter in the previous year, the firm posted ($0.65) earnings per share. As a group, sell-side analysts anticipate that FibroGen will post -0.91 EPS for the current year.
Institutional Trading of FibroGen
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Featured Articles
- Five stocks we like better than FibroGen
- Insider Buying Explained: What Investors Need to Know
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- How to Invest in Blue Chip Stocks
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- How Investors Can Find the Best Cheap Dividend Stocks
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.